On May 24, 2019, the Food and Drug Administration approved alpelisib PIQRAY, Novartis Pharmaceuticals Corporation in combination with fulvestrant for postmenopausal women, and men, with hormone receptor HR positive, human epidermal growth factor receptor 2 HER2 negative, PIK3CA mutated, advanced or metastatic breast cancer as detected by an FDA approved test following progression on or after an endocrine based regimen doxycycline heartburn PMC free article PMC3365847 PubMed 20237240